Colorado is currently home to 1807 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Denver, Aurora, Colorado Springs and Englewood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)
NCT05787821
Recruiting
The main objective of the study is to evaluate the safety, performance and clinical benefits of the Persona implant and its instrumentation in primary total knee arthroplasty
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Denver Hip & Knee, Inc., Parker, Colorado
Conditions: Knee Pain Chronic, Osteoarthritis, Knee, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Varus Deformity, Valgus Deformity, Flexion Deformity of Knee, Avascular Necrosis
Register for Updates
Bone, Exercise, Alendronate, and Caloric Restriction
NCT05764733
Recruiting
The purpose of this research is to identify strategies that minimize bone loss that occurs when older adults lose weight. Participation in this research will involve up to nine assessment visits and last up to two years.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
01/29/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Bone Loss
Register for Updates
Persona Revision Knee System Outcomes
NCT04821154
Recruiting
The study will evaluate the performance, clinical benefits and safety of the Persona Revision Knee System in patients who have received primary or revision total knee arthroplasty (TKA) treatment. This will be done using a multicenter, single-arm, consecutive series, retrospective cohort study with prospective follow-up.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Cornerstone Orthopaedics & Sports Medicine, Superior, Colorado
Conditions: Arthroplasty Complications, Infection, Knee Disease, Knee Osteoarthritis
Register for Updates
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
NCT03433274
Recruiting
Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP). Subjects in the Randomized cohort will be randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts will receive the trial device. The objective of the Clinical Trial to Evaluate t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: University of Colorado Hospital, Aurora, Colorado
Conditions: Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease
Register for Updates
DS-Connect®: The Down Syndrome Registry
NCT01950624
Recruiting
The goal of this study is to develop a registry for Down syndrome (DS) to facilitate research participation by individuals with Down syndrome. DS-Connect® is an online survey tool designed to collect demographic data and health information from individuals with DS. It is open to all people with Down syndrome. The purposes of DS-Connect® are: 1. To identify the various phenotypic manifestations of DS. 2. To identify individuals with DS who may be eligible for research studies or new clinical t... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/29/2025
Locations: Linda Crnic Institute for Down Syndrome, Aurora, Colorado
Conditions: Down Syndrome
Register for Updates
A Study of DF6002 Alone and in Combination With Nivolumab
NCT04423029
Recruiting
The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and in combination with Nivolumab in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: SCRI - HealthOne Denver, Denver, Colorado
Conditions: Solid Tumors
Register for Updates
Danon Disease Natural History Study
NCT06214507
Recruiting
The goal of this international observational study is to learn about the natural history of Danon disease in male patients \>8 years of age and female patients \<30 years of age. The key objectives include assessing change over time in cardiac structure (left ventricular mass and wall thickness), cardiac biomarkers, symptoms, and quality of life and the incidence of clinical events such as HF hospitalization, cardiac transplantation, and death.
Gender:
ALL
Ages:
8 years and above
Trial Updated:
01/27/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Danon Disease
Register for Updates
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
NCT05517811
Recruiting
The investigators hypothesize that abnormalities in thromboelastography (TEG) parameters in patients with liver, pancreas, biliary, esophageal, colorectal, and lung adenocarcinoma can serve as biomarkers for oncologic disease burden, cancer recurrence and overall survival as well as thrombotic and hemorrhagic post-operative complications. The investigators further hypothesize that there is histologic pathology correlates to pre-operative TEG abnormalities, and that it identifies patients with vi... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
01/27/2025
Locations: University of Colorado Denver, Aurora, Colorado
Conditions: Liver Cancer, Esophageal Cancer, Colorectal Cancer, Lung Adenocarcinoma, Control, Pancreas Cancer, Biliary Cancer
Register for Updates
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer
NCT05216432
Recruiting
This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, catalytic subunit alpha (PIK3CA) mutation in blood and/or tumor per local assessment. The study will evaluate RLY-2608 as a single agent for patients with unresectable or metastatic solid tumors. It will als... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: HealthONE, Denver, Colorado
Conditions: PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Endometrial Cancer
Register for Updates
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
NCT04704921
Recruiting
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (anti-VEGF)... Read More
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
01/27/2025
Locations: 177-Retina Consultants of Southern Colorado PC- Colorado Springs, Colorado Springs, Colorado
Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization
Register for Updates
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT03526835
Recruiting
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Rocky Mountain Cancer Centers, Lone Tree, Colorado
Conditions: Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
Register for Updates
A Phase 3 Study of Pacritinib in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03165734
Recruiting
This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count \<50,000/μL). Approximately 399 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 266 patients) or to P/C therapy (approximately 133 patients) Condition or disease: Primary Myelofibrosis/Post-Polycythemia Vera Myelofibrosis/ Post-essential Thromb... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: University of Colorado Cancer Center, Aurora, Colorado
Conditions: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Register for Updates